Update from Korea on the Lutonix SFA registry 12 month data
|
|
- Kerrie Walsh
- 5 years ago
- Views:
Transcription
1 Update from Korea on the Lutonix SFA registry 12 month data Prospective, Multicenter, Post-Market Registy Assessing the Clinical Use and Safety of the Lutonix Drug Coated Balloon in Femoropopliteal Arteries Je Hwan Won, MD Division of Interventional Radiology, Radiology Department Ajou University Hospital, S. Korea
2 Disclosure Speaker name: Je Hwan Won... I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s) v I do not have any potential conflict of interest
3 DCB reimbursement in Korea 2 DCBs for SFA 1 DCB for Popliteal Reimbursement of DCBs for Femoropopliteal artery 70% stenosis in De novo 50% stenosis in ISR 2 for SFA, 1 for Popliteal 1 bail-out stent can be reimbursed for the 50% residual stenosis or dissection On-going discussions for the expansion of DCB reimbursement indication (BTK, AV)
4 Not All DCBs are created Equal Lutonix 035 DCB Other DCB Carrier: Polysorbate & Sorbitol (IV approved carriers) PTX Dose: 2µg/mm 2 Plasma Half-Life: 6.9 hours Carrier: Urea PTX Dose: 3.0µg/mm 2 Plasma Half-Life: 72.5 hours
5 Other DCB Other DCB ng /g ng /g Downstream Safety in a Porcine Model Downstream Paclitaxel Concentration: Lutonix (2µg/mm 2 ) vs. Other DCB (3.0µg/mm 2 ) Skeletal Muscle Lutonix 1,3 60,8 47x More 28 day (1x dose) Other DCB Coronary Band LUTONIX LUTONIX Lutonix 1, x More 28 day (1x dose) Other DCB Kolodgie et al, JVIR D R1. Preclinical results may not be indicative of clinical performance. Different test methods may yield different results. Lutonix showed significantly lower downstream paclitaxel levels Coronary band BPV/LTNX/0816/0086c
6 LUTONIX Korean Registry Prospective, Multicenter, Post-Market Registry Assessing the Clinical Use and Safety of the LUTONIX 035 Drug Coated Balloon in Femoropopliteal Arteries
7 Study Design Study Design A Prospective, Multicenter, Single Arm, Post-Market Registry Objective Number of Patients/Sites Inclusion Criteria Exclusion Criteria Selected Endpoint To assess the clinical use and safety of the Lutonix Drug Coated Balloon Catheter in a heterogeneous patient population in real world clinical practice. Approximately 250 subjects at up to 16 sites in Korea Rutherford Clinical Category 4, Stenotic or obstructive vascular lesions Inadequate distal outflow Primary Effectiveness: Freedom from target lesion revascularization(tlr) at 12 months Primary Safety: Freedom at 30 days from the *composite endpoint *: target vessel revascularization (TVR) and target lesion revascularization (TLR), major amputation and major reintervention (new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis) of index limb and device- and procedure-related death.
8 Subject Disposition Lutonix Korea registry (N=249) Enrolled 249 (100.0%) Completed 6 month (180 days) 241 (96.8%) Completed 12 month (365 days) 232 (93.2%) Discontinued prematurely 16 (6.4%) Withdrawal of consent 1 (0.4%) Death 11 (4.4%) Lost to follow-up 2 (0.8%)
9 Baseline DCB Demographics Class. Description Korean registry (N=249) Age(Years) Mean (SD) 69.1±10.46 Gender Male 212 (85.1%) Female 37 (14.9%) DM 149 (59.8%) Risk Factor Dyslipidemia 49 (19.7%) Hypertension 176 (70.7%) Cigarette smoking 106 (42.6%) Class 1~2 45.5% Rutherford Grade Class % Class % Class 5~6 -
10 DCB Angiographic Demographics Classification Korean registry (N=249) Number of Lesions=338 Target Lesion Length (mm) (79.42) Calcification 256 / 338 (75.7%) Chronic Total Occlusion 143 / 338 (42.3%) Lesion Locations SFA 248 / 338 (73.3%) Proximal Popliteal 53 / 338 (15.6%) Mid & Distal Popliteal 37 / 338 (10.9%) Bail-out Stenting 22 / 249 (8.8%)
11 Pretreatment and bailout stenting Variables N=249 Comment Pretreatment Balloon angioplasty 225 / 249 (90.4%) Atherectomy 15 / 249 (6.0%) Others 1 / 249 (0.4%) Cutting balloon Post-DCB treatment Balloon angioplasty 20 / 249 (8.0%) Bail-out stenting 22 / 249 (8.8%) 20 BMS/ 2 Covered stent Device Success: 100.0% Procedural Success*: 96.3% *: residual stenosis > 30% and AE(death, stroke, MI, emergent surgical revascularization, significant distal embolization in the target limb, and thrombosis of the target vessel)
12 Primary Safety Endpoint Free from * composite events through 30 days N 247 / DAYS % [95% CI] 99.2% [96.8%, 99.8%] *: target vessel revascularization (TVR) and target lesion revascularization (TLR), major amputation and major reintervention (new bypass graft, jump/interposition graft revision, or thrombectomy / thrombolysis) of index limb and device- and procedure-related death.
13 Primary safety endpoint at 1 month Variables N=249 Comment TVR 1 TLR 1 LT SECOND TOE WOUND and 100% Stenosis Occlusion of LT. POPLITEAL ARTERY Major reintervention - Death - Procedure-related - Device-related - Major index limb amputation - * Minor index limb amputation *: was not in the list of primary safety endpoint 1 LT 4th toe ray amputation
14 2 composite events within 30 days EVENT 1 Primary treatment: Pre-dilatation + DCB only + Post-dilatation Over 50% residual stenosis 17 days Reason for Re-Intervention: LT SECOND TOE WOUND and 100% Stenosis Location: Target vessel and non-target lesion Treatment: PTA, Stenting EVENT 2 Primary treatment: Pre-dilatation + DCB only 20% residual stenosis 25 days Reason for Re-Intervention: Occlusion of LT POPLITEAL ARTERY Location: Target lesion Treatment: PTA, Stenting
15 Primary Efficacy Endpoint at 1 year Subjects Free from TLR Number of Subjects with TLR 180 DAYS DAYS 12 Estimates of Subjects Free from TLR [95% CI] 98.4% [95.7%, 99.4%] 95.0% [91.3%, 97.1%]
16 LUTONIX Global SFA Registry Prospective, Multicenter, Post-Market Registry Assessing safety, clinical benefit, and outcomes of the Lutonix 035 drug-coated balloon (DCB) in a heterogeneous, real-world patient population at 12 and 24 months in Femoropopliteal Arteries
17 Baseline DCB Demographics Global registry (N=691) Korean registry (N=249) Age, Mean ± SD (n) 68.2 ± 9.8 (691) 69.1±10.46 Male gender, % (n/n) 67.9% (469/691) 85.1% Obesity 24.7% (164/665) Current Smoker 36.9% (254/689) 42.6% Dyslipidemia 70.0% (484/691) 19.7% Diabetes 39.5% (273/691) 59.8% Hypertension 84.9% (587/691) 70.7% Rutherford Glade Class 1~2 20.6% (142/689) 45.5% Rutherford Glade Class % (461/689) 41.3% Rutherford Glade Class 4 7.4% (51/689) 13.2% Rutherford Glade Class 5~6 1.6% (11/689) -
18 DCB Angiographic Demographics Classification Global registry (N=691) Korean registry (N=249) > Two lesions treated 15.6% (108/691) Total Lesion Length (mm) ± 84.2 (685) Treated Length (mm) ± 89.7 (689) Calcification 50.2% (238/474) 75.7% Chronic Total Occlusion 31.2% (214/686) 42.3% Lesion Locations SFA 70.0% (483/690) 73.3% Proximal Popliteal 16.8% (116/690) 15.6% Mid & Distal Popliteal 13.1% (91/690) 10.9% Final %Diameter Stenosis 14.6 ± 18.6 (680) Bail-out Stenting 25.2% (174/690) 8.8% Dissection 18.4% (127/690) 2.8%
19 Lutonix Global SFA Real-World Registry 12 months results MEASURE % (n / N) Korean Registry 30-day Safety % (681/685) 99.2% Free from TLR 93.4% (605/648) 95.0% 1 Freedom at 30 days from TVR, major index limb amputation, and device-and procedure-related death ALL SAEs adjudicated. Study monitored.
20 Lutonix Global SFA Real-World Registry 24 months results MEASURE % (n / N) Free from TLR 89.3% (526/589) 1 Secondary endpoint. Clinical primary patency of the target lesion was reported by the investigator based on presenting symptoms and clinical exam.
21 Conclusions Lutonix DCB Korean registry data shows acceptable safety at 1 month and shows 98.4% at 6 months and further 95.0% at 1 year of freedom from TLR, respectively The results of Lutonix Korean registry are correspond to the results of the global registry. This study have great significance since it shows the efficacy and safety of Lutonix DCB for the large Asian population. Adequate vessel preparation seems to be a critical success factor for the drug delivery and the long-term result of DCB procedure Downstream effect should be considered when you re using multiple DCBs
22 Update from Korea on the Lutonix SFA registry 12 month data Prospective, Multicenter, Post-Market Registy Assessing the Clinical Use and Safety of the Lutonix Drug Coated Balloon in Femoropopliteal Arteries Je Hwan Won, MD Division of Interventional Radiology, Radiology Department Ajou University Hospital, S. Korea
ISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany
ISR-treatment The Leipzig experience with purely mechanical debulking Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich I have the following
More informationDrug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
More informationHow do I use mechanical debulking for the treatment of arterial occlusions
How do I use mechanical debulking for the treatment of arterial occlusions Sven Bräunlich, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich
More informationDCB in my practice: How the evidence influences my strategy. Yang-Jin Park
DCB in my practice: How the evidence influences my strategy Yang-Jin Park Associate Professor Division of Vascular Surgery, Department of Surgery Samsung Medical Center Sungkyunkwan University School of
More informationOutcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
More informationUpdate on the Levant 2 Clinical Trial Programme. Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany
Update on the Levant 2 Clinical Trial Programme Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany Disclosure Speaker name: Dierk Scheinert I have the following potential conflicts of interest
More informationBIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort
BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort Prof. Dr. Gunnar TEPE, Klinikum Rosenheim, Germany CCI on behalf of the BIOLUX P-III Investigators Disclosure
More informationPromise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD
Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD Associate Professor of Vascular Surgery University of New South Wales Sydney,
More informationThe Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience
The Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany Disclosure Speaker name: Dierk Scheinert I have
More informationHiroshi Ando, MD Kasukabe Chuo General Hospital Saitama, Japan
Hiroshi Ando, MD Kasukabe Chuo General Hospital Saitama, Japan Disclosure Hiroshi Ando, MD Kasukabe Chuo General Hospital I have the following potential conflicts of interest to report: Consulting Employment
More information12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany
12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany Disclosure Speaker name: Gunnar Tepe I have the following potential conflicts
More informationClinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry
Clinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry Alexander Zimmermann Department of Vascular and Endovascular Surgery Klinikum rechts der Isar
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationILLUMENATE FIH Direct DCB Cohort 12-Month Results
ILLUMENATE FIH Direct DCB Cohort 12-Month Results Stephan Duda Berlin Study Investigators: H. Schröder (PI), B. Lux, F. Rücker, M. Martorana, D. Meyer, H. Hartmann, S. Duda Disclosure Speaker name: S.
More informationLong Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA
Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA Disclosures John R. Laird Within the past 12 months, I or my spouse/partner have had a
More informationThe Crack and Pave technique for highly resistant calcified lesions. Manuela Matschuck MD University Hospital Leipzig Department Angiology
The Crack and Pave technique for highly resistant calcified lesions Manuela Matschuck MD University Hospital Leipzig Department Angiology Disclosure Speaker name: Dr. med. Manuela Matschuck I have the
More informationLutonix in AV fistula and Early look AV IDE trial data
Lutonix in AV fistula and Early look AV IDE trial data Jackie P Ho Dept of Cardiac, Thoracic & Vascular Surgery National University of Singapore NUHS, Singapore Lutonix in AV fistula and final AV IDE trial
More informationTOBA II 12-Month Results Tack Optimized Balloon Angioplasty
TOBA II 12-Month Results Tack Optimized Balloon Angioplasty William Gray, MD System Chief, Cardiovascular Division Main Line Health, Philadelphia, PA Dissection: The Primary Mechanism of Angioplasty Lesions
More informationChristian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide
2-Year Results Of The Tack Optimized Balloon Angioplasty (TOBA) Trial For Fem- Pop Lesions Demonstrates Safety and Efficacy Of The Tack Endovascular System In Repairing Focal Post-PTA Dissections Christian
More informationLutonix DCB in BTK Update on the BTK real world registry and RCT
Lutonix DCB in BTK Update on the BTK real world registry and RCT Prof. Dr. med. Dierk Scheinert Department of Interventional Angiology University Hospital Leipzig Disclosures Speaker: Prof. Dr. med. Dierk
More informationLatest Insights from the LEVANT II study and sub-group analysis
Latest Insights from the LEVANT II study and sub-group analysis Prof. Dr. med. Dierk Scheinert Division of Interventional Angiology University-Hospital Leipzig, Germany Conflicts of Interest Advisory Board
More informationThe Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD
The Role of Lithotripsy in Solving the Challenges of Vascular Calcium Thomas Zeller, MD 1 1 Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: X X
More informationCOMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions. Dierk Scheinert
COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions Dierk Scheinert Department of Angiology University Hospital Leipzig, Germany Disclosure
More informationThe latest evidences from the DES trials in peripheral arterial disease
The latest evidences from the DES trials in peripheral arterial disease Michael D. Dake, MD Thelma and Henry Doelger Professor Stanford University School of Medicine Disclosure Speaker name: Michael D.
More informationRotarex mechanical debulking: The Leipzig experience in patients
Rotarex mechanical debulking: The Leipzig experience in 1.200+ patients Dierk Scheinert, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Dierk Scheinert
More informationKlinikum Rosenheim Department of Diagnostic and Interventional Radiology
Klinikum Rosenheim Department of Diagnostic and Interventional Radiology Is Directional Atherectomy (Silverhawk Or Turbohawk) With DEB, Better Than DEB Alone: Based On The DEFINITIVE AR RCT: 1-Year Results
More informationClinical benefits on DES Patient s perspectives
Clinical benefits on DES Patient s perspectives Dr. Skyi Pang Vascular Surgeon Department of Surgery Pamela Youde Nethersole Eastern Hospital Hong Kong Disclosure Speaker name: Skyi Pang... I have the
More informationMaximizing Outcomes in a complex population with Drug-coated balloon
Maximizing Outcomes in a complex population with Drug-coated balloon March 13, 2018 Chumpol Wongwanit, MD Siriraj Hospital, Mahidol University, Bangkok, Thailand LINC Asia-Pacific 2018, Hong Kong Disclosure
More informationLutonix AV Clinical Trial
Long Term Effects of LUTONIX 035 DCB Catheter Interim 24 Month Results Scott O. Trerotola, MD, for the Lutonix AV Investigators Stanley Baum Professor of Radiology Professor of Radiology in Surgery Associate
More information2 Year Results from the MDT SFA Japan Trial - DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA
2 Year Results from the MDT- 2113 SFA Japan Trial - DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA Osamu Iida, MD - Kansai Rosai Hospital, Hyogo, Japan Hiroyoshi Yokoi,
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationMichael K. W. Lichtenberg, MD, FESC Westfälische Wilhelms-Universität Münster. Dierk Scheinert, M.D. Universitätsklinikum Leipzig AöR
Michael K. W. Lichtenberg, MD, FESC Westfälische Wilhelms-Universität Münster Dierk Scheinert, M.D. Universitätsklinikum Leipzig AöR Disclosure Dierk Scheinert, MD Advisory Board /Consultant: Abbott, Biotronik,
More informationOCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter. Patrick Muck, MD
OCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter Patrick Muck, MD Chief, Division of Vascular Surgery Good Samaritan Hospital Cincinna
More informationComparison of Angiographic Dissection Patterns Caused by Long vs Short Balloons During Balloon Angioplasty for Chronic Femoropopliteal Occlusions
Comparison of Angiographic Dissection Patterns Caused by Long vs Short Balloons During Balloon Angioplasty for Chronic Femoropopliteal Occlusions Michinao Tan, MD Tokeidai Memorial Hospital Cardiovascular
More informationDCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
More informationLUTONIX DCB in BTK Update on the BTK clinical program & single center experience
LUTONIX DCB in BTK Update on the BTK clinical program & single center experience Prof. Dr. med. Dierk Scheinert Department of Interventional Angiology University Hospital Leipzig Disclaimer 1. The information
More informationAngiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis-
Angiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis- Masahiko Fujihara Kishiwada Tokushukai Hospital, Osaka, Japan Disclosure
More informationAlternative concepts for drug delivery in BTK arteries the LIMBO project
Alternative concepts for drug delivery in BTK arteries the LIMBO project Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany 1 Disclosure Speaker s name: Dierk
More informationLong-term Zilver PTX Data from Japan: 5-year Results in the Real World
Long-term Data from Japan: 5-year Results in the Real World Hiroyoshi Yokoi, MD Department of Cardiovascular Medicine Fukuoka Sanno Hospital Fukuoka, Japan On behalf of the Investigators Disclosure Speaker
More informationDrug-coated balloons in BTK:
Drug-coated balloons in BTK: Where do we stand and what are the open questions? Dr. Marc Bosiers LINC 2019 - Leipzig My disclosures x o I do not have any potential conflicts of interest to report o I have
More informationThe importance of scientific evidence. Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern
The importance of scientific evidence Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner... I have the following potential
More informationZilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results
Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results Hiroyoshi Yokoi, MD, Fukuoka Sannou Hospital Fukuoka, Japan On behalf
More informationDealing with Calcification in BTK Arteries: Is Lithoplasty the Answer?
Dealing with Calcification in BTK Arteries: Is Lithoplasty the Answer? Andrew Holden, MBChB, FRANZCR, EBIR Director of Interventional Radiology Auckland, New Zealand LINC 2017 January 25 th 2017 Disclosure
More informationDierk Scheinert, MD. Department of Angiology University Hospital Leipzig, Germany
The RANGER clinical trial programme: 12-month results from the RANGER RCT and first look at the COMARE I study of RANGER vs. IN.PACT for femoropopliteal lesions Dierk Scheinert, MD Department of Angiology
More informationCurrent Status of DCB Experience with Non- Femoropopliteal Applications (Dialysis, Tibial, Venous)
Current Status of DCB Experience with Non- Femoropopliteal Applications (Dialysis, Tibial, Venous) Saher Sabri, MD University of Virginia Health System Charlottesville, Virginia Dialysis vascular access
More informationMICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES. Medtronic Further. Together
DRUG-COATED BALL0ON TREATMENT FOR PATIENTS WITH INTERMITTENT CLAUDICATION: INSIGHTS FROM THE IN.PACT GLOBAL FULL CLINICAL COHORT MICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES Medtronic Further. Together
More informationJanuary 23, Vascular and oncological interventional radiology Paris Descartes University
January 23, 2019 First time data release: Paclitaxel-coated balloon in below-the-knee lesions: 6-months results from the Ranger BTK single center study Dr. Costantino Del Giudice Prof Marc Sapoval Vascular
More informationMichael K. W. Lichtenberg MD, FESC on behalf of KANSHAS 1 investigators; Tepe G, Müller-Hülsbeck S, Deloose K, Verbist J, Goverde P, Zeller T
Interim 30-day analysis from the KANSHAS 1 study of the novel KANSHAS drug coated balloon for treatment of femoropopliteal occlusive disease; a latest first-in-human study Michael K. W. Lichtenberg MD,
More informationLutonix AV Clinical Trial
Long Term Effects of LUTONIX 035 DCB Catheter Interim 24 Month Results Ta-Wei Su MD Vascular surgery CGMH Taiwan Disclosure I have the following potential conflicts of interest to report: Consulting Employment
More informationMechanical thrombectomy in peripheral interventions: A multitask and effective tool in a widening scenario. Current evidence and technical tips.
Mechanical thrombectomy in peripheral interventions: A multitask and effective tool in a widening scenario. Current evidence and technical tips. Dr. Bruno Freitas, Prof., MD Department of Interventional
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report G. Biro, M. Bosiers on behalf of ZILVERPASS Study Group Disclosure Speaker
More informationDo we really need a stent in long SFA lesions? No: DEB is the answer
Do we really need a stent in long SFA lesions? No: DEB is the answer Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen Germany My Disclosures: Advisory Board: Medtronic-Invatec,
More informationImportance of Thorough Vessel Preparation Followed By Anti- Restenotic Therapy: An Update from the DEFINITIVE AR Study
Importance of Thorough Vessel Preparation Followed By Anti- Restenotic Therapy: An Update from the DEFINITIVE AR Study Gunnar Tepe, MD Romed Klinikum, Rosenheim, Germany On behalf of the DEFINITIVE AR
More informationThe results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan
The results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan COI disclosure Disclosure Speaker name: Taku Kato... I have the
More informationThe Freeway Stent Study: the 12 Months results highly favor the use of DEB in combination with stenting
The Freeway Stent Study: the 12 Months results highly favor the use of DEB in combination with stenting J. Tacke, K.A. Hausegger, H. Schröder, J. Dambach, S. Stahnke, S.Müller-Hülsbeck, MD, EBIR, FCIRSE,
More informationBioMimics 3D in my Clinical Practice
BioMimics 3D in my Clinical Practice M Lichtenberg M.D. Vascular Centre Arnsberg / German Venous Centre Arnsberg CAUTION: Investigational Device. Limited by Federal (or United States) Law to Investigational
More informationUpdate on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria
Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee Marianne Brodmann, MD Medical University Graz Graz, Austria Critical Limb Ischemia Infrapopliteal arterial disease is a leading source
More informationThe TANGO Trial: A phase II below-the-knee study investigating the adventitial micro-infusion of Temsirolimus after PTA or atherectomy
The TANGO Trial: A phase II below-the-knee study investigating the adventitial micro-infusion of Temsirolimus after PTA or atherectomy Ian Cawich, MD Arkansas Heart Hospital Little Rock, Arkansas, USA
More informationCutting/scoring balloon Cryoplasty Drug-eluting balloon Brachytherapy Debulking Restent (BMS or DES) John R. Laird, MD
Current Treatment of Femoropopliteal Instent Restenosis Professor of Medicine Medical Director of the Vascular Center UC Davis Medical Center SFA In-stent Restenosis Common: 18%- 40% at 12 months in recent
More informationOne Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller
One Year after In.Pact Deep: Lessons learned from a failed trial Prof. Dr. Thomas Zeller Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: x Consulting:
More informationFuture Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?
Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit? John R. Laird Adventist Heart and Vascular Institute St. Helena, CA Disclosure Speaker name: John R. Laird... I have
More informationAdventitial Drug Infusion to Prevent Restenosis
Adventitial Drug Infusion to Prevent Restenosis Marianne Brodmann, M.D. University of Graz Graz, Austria Disclosure Speaker name: Marianne Brodmann... I have the following potential conflicts of interest
More informationUpdate on the OPTIMIZE BTK Trial. Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria
Update on the OPTIMIZE BTK Trial Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria Disclosure Speaker name: Marianne Brodmann, MD... I have the following potential conflicts
More informationCatheter-Directed Thrombolysis for Acute Limb Ischemia. Hwan Jun Jae MD Seoul National University Hospital Seoul, Korea
Catheter-Directed Thrombolysis for Acute Limb Ischemia Hwan Jun Jae MD Seoul National University Hospital Seoul, Korea Disclosure Speaker name: Hwan Jun Jae... I have the following potential conflicts
More informationMassimiliano Fusaro, MD on behalf of ISAR-STATH Investigators. Deutsches Herzzentrum München, Technische Universität München Munich - Germany
Intravascular Stenting and Angiographic Results: Randomized Comparison of STenting, Stenting after Paclitaxel-eluting balloon and ATHerectomy in patients with symptomatic Peripheral Artery Disease - Results
More informationSFA CTO Lesion Management laser or directional atherectomy?
SFA CTO Lesion Management laser or directional atherectomy? Kevin, Chung-Ho Hsu, M.D. Setion of Peripheral Vascular Disease, Division of Cardiology, China Medical University Hospital, Taichung, Taiwan
More informationIs combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?
Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial G. Torsello Münster Disclosure Speaker name: G. Torsello... I have
More informationTreating in-stent occlusions with the Rotarex catheter : The ROBINSON study
Treating in-stent occlusions with the Rotarex catheter : The ROBINSON study final 6-month results in 30 patients Dr. Michel Bosiers Conflict of interest have the following potential conflicts of interest
More informationIN.PACT AV Access IDE Study Full Baseline Data. Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators
IN.PACT AV Access IDE Study Full Baseline Data Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators Disclosures Speaker name: Robert Lookstein, MD... I have the following
More informationExcimer Laser angioplasty for femoro-popliteal disease. Sendai Kousei Hospital, Tokyo Kamata Hospital Naoto Inoue MD, FSCAI, FJCC, FAHA
Excimer Laser angioplasty for femoro-popliteal disease Sendai Kousei Hospital, Tokyo Kamata Hospital Naoto Inoue MD, FSCAI, FJCC, FAHA Speaker s name: Naoto Inoue I have the following potential conflicts
More informationTOBA Trial 12 months Results
Tack Optimized Balloon Angioplasty: TOBA Trial 12 months Results New Paradigm for Managing Post PTA Dissections Marc Bosiers, MD A.Z. St. Blasius Hospital, Belgium Disclosure Speaker name: Dr. Marc Bosiers
More informationNeuestes aus der Therapie der pavk. beschichtete Stents + Ballons. Karls-University. Eberhard-Karls. of Tubingen Department of Diagnostic Radiology
Eberhard-Karls Karls-University of Tubingen Department of Diagnostic Radiology Neuestes aus der Therapie der pavk Berlin Dezember 08 beschichtete Stents + Ballons Gunnar Tepe 1 Local Drug Delivery Basic
More informationBrachytherapy for In-Stent Restenosis: Is the Concept Still Alive? Matthew T. Menard, M.D. Brigham and Women s Hospital Boston, Massachussetts
Brachytherapy for In-Stent Restenosis: Is the Concept Still Alive? Matthew T. Menard, M.D. Brigham and Women s Hospital Boston, Massachussetts Disclosure Speaker name: Matthew T. Menard... x I do not have
More informationAtherectomy: Jetstream and Directional. George S. Chrysant, M.D.
Atherectomy: Jetstream and Directional George S. Chrysant, M.D. Disclosures Abbott Vascular: MAB, consultant, proctor Abiomed: consultant Boston Scientific: MAB, consultant, proctor Medicines Company:
More informationAdventitial Drug Therapy Below-the-Knee: Update on LIMBO and TANGO
Adventitial Drug Therapy Below-the-Knee: Update on LIMBO and TANGO Ehrin J. Armstrong, MD, FACC University of Colorado School of Medicine VA Eastern Colorado Healthcare System Denver, Colorado, USA Disclosure
More informationThe latest generation DEB
The latest generation DEB V. Riambau, MD. PhD Prof. and Chief of Vascular Surgery Division, Cardiovascular Institute, Hospital Clínic of Barcelona University of Barcelona Consultant: Bolton Medical/ Medtronic/
More informationMichael K.W. Lichtenberg, MD
Ranger All-Comer Registry Treatment of femoropopliteal atherosclerotic lesions using the Drug eluting Balloon Ranger: An All Comers Registry Michael K.W. Lichtenberg, MD Klinikum Arnsberg Arnsberg, Germany
More informationClinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD
Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD Asan Medical Center, Heart Institute, University of Ulsan College of Medicine, Werk et al. Circulation Cardiovasc Intervent 2012
More informationSafety and Feasibility of Intravascular Lithotripsy for Treatment of Common Femoral Artery Stenoses
Safety and Feasibility of Intravascular Lithotripsy for Treatment of Common Femoral Artery Stenoses Pr Marianne Brodmann, MD Univ. Klinik für Innere Medizin Medizinische Universtität Graz 1 Disclosure
More informationQizhuang Jin. Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China
Safety and Efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (APERTO OTW ) for Arteriovenous Fistulae Stenosis: a Prospective, Multicenter, Randomized Controlled Trial APERTO
More informationAtherectomy is Still Live and Effective. John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System
Atherectomy is Still Live and Effective John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System Why is Atherectomy Still Alive? Improved devices Better data
More informationLUTONIX AV Clinical Trial
LUTONIX AV Clinical Trial A Prospective, Global, Multicenter, Randomized, Controlled Study Comparing LUTONIX 035 AV Drug Coated Balloon PTA Catheter vs. Standard Balloon PTA Catheter for the Treatment
More informationOutcome of DCB and PTA post stenting in occluded versus stenotic lesions subgroup analysis of the randomized Freeway Stent Study
Outcome of DCB and PTA post stenting in occluded versus stenotic lesions subgroup analysis of the randomized Freeway Stent Study J. Tacke, K.A. Hausegger, H. Schröder, J. Dambach, S. Stahnke, S.Müller-Hülsbeck,
More informationLIBERTY 360 Study. 15-Jun-2018 Data 1. Olinic Dm, et al. Int Angiol. 2018;37:
LIBERTY 360 Study LIBERTY is a prospective, observational, multi-center study to evaluate procedural and long-term clinical and economic outcomes of endovascular device interventions in patients with symptomatic
More information2-YEAR DATA SUPERA POPLITEAL REAL WORLD
2-YEAR DATA SUPERA POPLITEAL REAL WORLD Enrique M. San Norberto. Angiology and Vascular Surgery. Valladolid University Hospital. Valladolid. Spain. Disclosure Speaker name: ENRIQUE M. SAN NORBERTO I have
More informationThe LIMBO trial: a RCT investigating adventitial dexamethasone infusion to prevent restenosis in BTK arteries utilizing a novel angiographic endpoint
The LIMBO trial: a RCT investigating adventitial dexamethasone infusion to prevent restenosis in BTK arteries utilizing a novel angiographic endpoint Dr. Ulrich Beschorner Universitäts Herzzentrum Freiburg
More informationThe essentials for BTK procedures: wires, balloons, what else
A comprehensive approach to diabetic patient Tx The essentials for BTK procedures: wires, balloons, what else Dai-Do Do Clinical and Interventional Angiology Cardiovascular Department Disclosure Speaker
More informationAtherectomy with thrombectomy of. Rotarex S : The Leipzig experience
Atherectomy with thrombectomy of femoropopliteal occlusions with Rotarex S : The Leipzig experience Dr. Bruno Freitas, Prof., MD Department of Interventional Angiology, Universität Leipzig, Germany Santa
More informationDrug-Eluting Balloon Angioplasty versus Bare Metal Stents for Femoropopliteal Disease in Real-World Experience
Drug-Eluting Balloon Angioplasty versus Bare Metal Stents for Femoropopliteal Disease in Real-World Experience Maria Doyle, M.Eng; Hilary Coffey, M.D. Ravindra Gullipalli, MBBS, FRCR St. Clare s Mercy
More informationPaclitaxel-coated versus Plain Balloon Angioplasty in the Treatment of Infrainguinal Vein Bypass Stenosis
Paclitaxel-coated versus Plain Balloon Angioplasty in the Treatment of Infrainguinal Vein Bypass Stenosis T. Hölzenbein, A. Ugurluoglu, M. Aspalter, W. Hitzl, K. Linni Dep Vascular & Endovascular Surgery
More informationKoen Keirse, MD RZ Tienen, Belgium
Clinical Benefits of the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection from the ENTRAP Study Koen Keirse, MD RZ Tienen, Belgium Disclosure Speaker name: Koen Keirse...
More informationLuminor DCB in femoropopliteal lesions
Luminor DCB in femoropopliteal lesions EffPac trial results and solo DCB study design Marcus Thieme, MD Department of Angiology/ Cardiology/ Diabetology Regiomed Vascular Center Sonneberg Clinic for Internal
More informationLong-term results with interwoven nitinol stents vs. BMS vs. DCB
Long-term results with interwoven nitinol stents vs. BMS vs. DCB Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany Disclosure Advisory Board /Consultant: Abbott,
More informationFirst time data release: Initial experience with the temporary Spur Stent System: DEEPER Trial first-in-man results Jihad A. Mustapha, MD, FACC,
First time data release: Initial experience with the temporary Spur Stent System: DEEPER Trial first-in-man results Jihad A. Mustapha, MD, FACC, FSCAI Associate Professor of Medicine Michigan State University,
More informationNovel concept for drug delivery in infrapopliteal arteries The LIMBO trial
Novel concept for drug delivery in infrapopliteal arteries The LIMBO trial Prof. Dr. med. Dierk Scheinert Division of Interventional Angiology University Hospital Leipzig, Germany 1 Disclosure Advisory
More informationUpdate on the Ranger clinical trial programme
Update on the Ranger clinical trial programme Dierk Scheinert, MD Universitätsklinikum Leipzig, Leipzig, Germany on behalf of the RANGER SFA investigators Disclosure Speaker s name: Dierk Scheinert I have
More information